Latest From CureTech Ltd.
Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.
After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.
Day-by-day updates from the J.P. Morgan Healthcare Conference Jan. 11-14 in San Francisco.
BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.
- Large Molecule
- Therapeutic Areas
- Middle East
- Parent & Subsidiaries
- CureTech Ltd.
- Senior Management
Michael Schickler, PhD, CEO
Moti Hacham, VP, Fin.
Rinat Rotem-Yehudar, PhD, VP, R&D
- Contact Info
Phone: (972) 8 932 4000
42 Hayarkon St.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.